AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High Following Analyst Upgrade

AnaptysBio, Inc. (NASDAQ:ANAB) shares reached a new 52-week high during trading on Wednesday after Barclays raised their price target on the stock from $78.00 to $79.00. Barclays currently has an overweight rating on the stock. AnaptysBio traded as high as $58.50 and last traded at $58.47, with a volume of 202416 shares. The stock had previously closed at $52.83.

A number of other brokerages also recently weighed in on ANAB. Truist Financial raised their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, November 10th. Stifel Nicolaus reduced their price objective on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. UBS Group began coverage on AnaptysBio in a research note on Wednesday, January 7th. They set a “buy” rating and a $70.00 price objective for the company. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Finally, Wall Street Zen downgraded AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and an average price target of $68.67.

Insiders Place Their Bets

In other news, CFO Dennis Mulroy sold 15,725 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $44.85, for a total transaction of $705,266.25. Following the sale, the chief financial officer owned 9,401 shares of the company’s stock, valued at $421,634.85. This trade represents a 62.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Daniel Faga sold 15,309 shares of AnaptysBio stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $43.26, for a total transaction of $662,267.34. Following the completion of the sale, the chief executive officer owned 458,139 shares of the company’s stock, valued at $19,819,093.14. This represents a 3.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 156,280 shares of company stock valued at $7,254,939. Company insiders own 33.50% of the company’s stock.

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Company announced a planned spin‑off of its biopharma operations into a new public company, “First Tracks Biotherapeutics,” targeted for Q2 2026 (potentially late April). Management frames the move as a value‑unlocking separation of distinct assets, which often leads to re‑rating of the parent and spun entity. AnaptysBio to Spin Off Biopharma Portfolio
• Positive Sentiment: Q4 results beat expectations: EPS $1.58 vs. consensus $0.89 and revenue $108.3M vs. $87.1M est. The beat supports the thesis that commercial/royalty streams are ramping and reduces near‑term execution risk. AnaptysBio Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: Analysts raised targets and ratings: Barclays moved to Overweight with a $79 PT and H.C. Wainwright raised its PT to $66 with a Buy — these upgrades increase investor confidence and provide fresh upside reference points. Benzinga Coverage ANAB PT Raised to $66 at H.C. Wainwright
• Positive Sentiment: Commercial upside from partner GSK: GSK reported strong Jemperli sales growth (~>13% QoQ to $343M in Q4), which implies meaningful and growing royalty flows to AnaptysBio under certain scenarios; management reiterated milestone/royalty expectations. Anaptys Provides Update on Business Separation and Announces Q4 and FY2025 Results
• Neutral Sentiment: Reported short‑interest data in recent feeds appears inconsistent (zero/NaN values and 0.0 days to cover) and likely not meaningful; no clear short squeeze signal from these reports. Market data / short interest summary
• Negative Sentiment: Despite the beat, the company still reported a negative net margin and an extremely negative return on equity (large historical losses reflected in ROE), signaling underlying profitability and capital‑efficiency issues that could temper valuation until the spin‑off and royalty streams fully materialize. Q4/FY2025 Press Release

Hedge Funds Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently modified their holdings of ANAB. Smartleaf Asset Management LLC lifted its holdings in AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 821 shares during the period. Larson Financial Group LLC lifted its stake in shares of AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of AnaptysBio by 24.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 263 shares during the period. Bessemer Group Inc. boosted its holdings in shares of AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after buying an additional 1,292 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of AnaptysBio by 940.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares during the last quarter.

AnaptysBio Stock Up 12.8%

The firm has a market capitalization of $1.65 billion, a PE ratio of -21.13 and a beta of 0.32. The stock’s fifty day simple moving average is $49.81 and its 200 day simple moving average is $38.50.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The firm had revenue of $108.25 million during the quarter, compared to the consensus estimate of $87.09 million. On average, analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its board has approved a share repurchase program on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.